NYSE:EVH - Evolent Health Stock Price, News & Analysis

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health Inc (NYSE:EVH) announced its earnings results on Tuesday, August, 6th. The technology company reported ($0.26) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.29) by $0.03. The technology company had revenue of $192 million for the quarter, compared to analysts' expectations of $192.51 million. Evolent Health had a negative net margin of 14.67% and a negative return on equity of 6.47%. The business's revenue for the quarter was up 33.1% on a year-over-year basis. During the same period last year, the firm earned ($0.03) earnings per share. View Evolent Health's Earnings History.

Evolent Health is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Evolent Health.

9 analysts have issued twelve-month price objectives for Evolent Health's stock. Their predictions range from $10.00 to $35.00. On average, they expect Evolent Health's stock price to reach $21.7222 in the next twelve months. This suggests a possible upside of 209.4% from the stock's current price. View Analyst Price Targets for Evolent Health.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolent Health.

News coverage about EVH stock has been trending positive on Monday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evolent Health earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the technology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Evolent Health.

Some companies that are related to Evolent Health include R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Chipotle Mexican Grill (CMG), Advanced Micro Devices (AMD), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Mobileye (MBBYF) and NVIDIA (NVDA).

(EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.95%), BlackRock Inc. (6.00%), Riverbridge Partners LLC (4.12%), Eagle Asset Management Inc. (2.24%), Cortina Asset Management LLC (2.03%) and Marshall Wace LLP (1.95%). Company insiders that own Evolent Health stock include Cheryl Scott, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley, Thomas Peterson III and Unitedhealth Group Inc. View Institutional Ownership Trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Waddell & Reed Financial Inc., D. E. Shaw & Co. Inc., Eagle Asset Management Inc., Invesco Ltd., Riverbridge Partners LLC, First Trust Advisors LP and Cubist Systematic Strategies LLC. Company insiders that have sold Evolent Health company stock in the last year include Jonathan Weinberg, Lydia Stone and Thomas Peterson III. View Insider Buying and Selling for Evolent Health.

EVH stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Vanguard Group Inc., Canada Pension Plan Investment Board, Prudential Financial Inc., Voce Capital Management LLC, Nuveen Asset Management LLC, Marshall Wace North America L.P. and Handelsbanken Fonder AB. Company insiders that have bought Evolent Health stock in the last two years include Kenneth A Samet and Michael D'amato. View Insider Buying and Selling for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $7.02.

Evolent Health has a market capitalization of $593.33 million and generates $627.06 million in revenue each year. The technology company earns $-52,660,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Evolent Health employs 3,800 workers across the globe.View Additional Information About Evolent Health.

The official website for Evolent Health is http://www.evolenthealth.com/.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.